PSIL ADVISORSHARES PSYCHEDELICS ETF
- 1.230
- +0.010+0.82%
Jim Cramer: This Industrial Company Is 'Absolutely Terrific', Recommends Buying Modine Manufacturing
On CNBC's "Mad Money Lightning Round," Jim Cramer believes in Moderna, Inc. (NASDAQ:MRNA).On May 14, Evercore ISI Group analyst Cory Kasimov initiated coverage on Moderna with an In-Line rating and an
Earnings Call Summary | NRX Pharmaceuticals(NRXP.US) Q1 2024 Earnings Conference
The following is a summary of the NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript:Financial Performance:NRx Pharmaceuticals reported a Q1 2024 net loss of $6.5 million, a reduction o
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersArcutis Biotherapeutics (NASDAQ:ARQT) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1
Notable Earnings After Tuesday's Close
Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday.Shares of Seritage Growth Properties (NYSE:SRG) fell sharply in today's pre-market trading after
Compass Pathways Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 1357.99% HC Wainwright & Co. → $120 Reiterates Buy → Buy 04/30/2024 — Cantor Fitzgerald Reiter
Earnings Call Summary | COMPASS Pathways(CMPS.US) Q1 2024 Earnings Conference
The following is a summary of the COMPASS Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript:Financial Performance:COMPASS Pathways had a net cash usage in operations of $20.8 million in Q1 2024 and
HC Wainwright & Co. Maintains Buy on Mind Medicine, Lowers Price Target to $35
HC Wainwright & Co. analyst Patrick Trucchio maintains Mind Medicine (NASDAQ:MNMD) with a Buy and lowers the price target from $75 to $35.
Mind Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 280.43% HC Wainwright & Co. $75 → $35 Maintains Buy 04/15/2024 117.39% Leerink Partners → $20 I
Mind Medicine (MindMed) Inc. (MNMD) Q1 2024 Earnings Call Transcript Summary
The following is a summary of the Mind Medicine (MindMed) Inc. (MNMD) Q1 2024 Earnings Call Transcript:Financial Performance:Mind Medicine raised approximately $175 million from an oversubscribed unde
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:KAYS) has been awarded a license by the Oregon Health Authority to operate a Psilocybin Service Center.Oregon is the only state in
Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S.
-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life--People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed
Mind Medicine Q1 2024 GAAP EPS $(1.14) Misses $(0.53) Estimate
Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(0.53) by 115.09 percent. This is a 75.38 percent decrease over losses of $(0
Analyst Ratings For Intra-Cellular Therapies
Throughout the last three months, 18 analysts have evaluated Intra-Cellular Therapies (NASDAQ:ITCI), offering a diverse set of opinions from bullish to bearish.The following table provides a quick ove
Compass Pathways Reports Q1 Cash And Cash Equivalents Of $262.9M
Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million.The full-year 2024 net cash used in operating activities is expected to be in the
Compass Pathways Q1 2024 GAAP EPS $(0.55) Misses $(0.48) Estimate
Compass Pathways Q1 2024 GAAP EPS $(0.55) Misses $(0.48) Estimate
Compass Pathways Announced Topline Results From An Open-label Phase 2 Study Of COMP360 Psilocybin Treatment For Post-Traumatic Stress Disorder, The Study Met Its Primary Safety Endpoint And Available Secondary Efficacy Endpoints
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observedEarly and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5
Intra-Cellular Therapies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 26.39% Needham → $90 Reiterates Buy → Buy 05/07/2024 26.39% Needham → $90 Reiterates → Buy 04/2
"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment
The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), scheduling a meeting next mon
Intra-Cellular Therapies | 10-Q: Quarterly report